Associated Papers
Molecular Profiling of KRAS, NRAS, and BRAF in Colorectal Cancer: Insights From a Libyan Cohort.
Tawel HM et al.
Cureus, 2025
KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer.
Radanova M et al.
International Journal of Molecular Sciences, 2023
Complete Screening of Exons 2, 3, and 4 of KRAS and NRAS Genes Reveals a Higher Number of Clinically Relevant Mutations than Food and Drug Administration Quantitative Polymerase Chain Reaction-Based Commercial Kits.
Sánchez-Ibarra HE et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion, 2020
Highly sensitive and selective detection of single-nucleotide polymorphisms using gold nanoparticle MutS enzymes and a micro cantilever resonator.
Park C et al.
Talanta, 2019
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
"Squirrel" Primer-Based PCR Assay for Direct and Targeted Sanger Sequencing of Short Genomic Segments.
Ebili HO et al.
Journal of Biomolecular Techniques : Jbt, 2017
SensiScreen®KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations.
Riva A et al.
Plos One, 2017
Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran.
Koochak A et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2016
Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression.
de Vries NA et al.
Cell Reports, 2015
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Yoon HH et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
Imamura Y et al.
Molecular Cancer, 2014
EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.
Chowdhuri SR et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2012
Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
Borràs E et al.
Bmc Cancer, 2011
SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics.
Fariña Sarasqueta A et al.
The Journal of Molecular Diagnostics : Jmd, 2011
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.
Arcila M et al.
The Journal of Molecular Diagnostics : Jmd, 2011
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue.
Tol J et al.
Journal of Cellular and Molecular Medicine, 2010
Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer.
Yunxia Z et al.
Bmc Medical Genetics, 2010
KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.
Gaedcke J et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 2010
KRAS mutation detection in Tunisian sporadic coloractal cancer patients with direct sequencing, high resolution melting and denaturating high performance liquid chromatography.
Karim B et al.
Cancer Biomarkers : Section a of Disease Markers, 0